Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 0.9 Normal Saline Clear all

Conditions: Degenerative Disc Disease
Interventions: NuQu, Placebo; Biological · Other
Lead sponsor: ISTO Technologies, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Santa Monica, California + 7 more

Conditions: Headache, Occipital Nerve Block
Interventions: Bupivacaine, Lidocaine, Dexamethasone, Normal saline, Greater/lesser occipital nerve blocks; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions: BQ123, Saline; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Amyotrophic Lateral Sclerosis
Interventions: RNS60; Drug
Lead sponsor: Mario Negri Institute for Pharmacological Research; Other
Eligibility: 18 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions: Aminophylline, Placebo; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Myocardial Infarction, Moderate Renal Impairment
Interventions: CSL_112, Placebo; Biological · Other
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 13
States / cities: Birmingham, Alabama • Huntsville, Alabama • Concord, California + 10 more

Conditions: Pulmonary Emphysema in Alpha-1 PI Deficiency
Interventions: Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP; Biological · Other
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 10
States / cities: Phoenix, Arizona • Gainesville, Florida • Leesburg, Florida + 7 more

Conditions: Acute Respiratory Distress Syndrome, Infections
Interventions: Rhu-pGSN, normal saline; Drug
Lead sponsor: BioAegis Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 7 more

Conditions: Acute Blood Loss Anemia, Osteoarthritis, Hip
Interventions: Tranexamic acid, Placebo; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions: Trilaciclib, Placebo, Gemcitabine, Carboplatin; Drug
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more

Conditions: Cystic Fibrosis
Interventions: Gallium nitrate, Normal Saline; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Birmingham, Alabama • La Jolla, California • Denver, Colorado + 20 more

Conditions: Infections, Intestinal
Interventions: Drug: GSK2251052, Meropenem, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 12
States / cities: Mobile, Alabama • Long Beach, California • Torrance, California + 9 more

Conditions: Heart Disease Congenital Complex
Interventions: Hydrocortisone, Normal Saline; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Day to 28 Days
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer, Pain, Postoperative, BRCA1 Mutation, BRCA2 Mutation, Breast Diseases, Neoplasms
Interventions: Botulinum Toxin Type A, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Anhedonia, Inflammation, Anxiety, Aging, Depression
Interventions: Endotoxin, Placebo; Biological
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 60 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: Eribulin, Carboplatin; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Venezuelan Equine Encephalitis Virus Infection
Interventions: Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate, 0.9% saline placebo; Biological · Other
Lead sponsor: Ichor Medical Systems Incorporated; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Wound, Foot, Diabetic Foot Ulcer (DFU), Venus Leg Ulcer
Interventions: Microlyte®, IP 1: Membrane Wrap - Hydro; Device
Lead sponsor: Capsicure, LLC; Network
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 7
States / cities: San Diego, California • Coral Gables, Florida • Miami, Florida + 3 more

Conditions: Critical Illness, Acute Kidney Injury
Interventions: 0.9% Saline, Physiologically-balanced isotonic crystalloid; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 10,421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Bowel Obstruction
Interventions: IV morphine sulfate, EXPAREL (bupivacaine liposome injectable suspension); Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Riverdale, Georgia

Conditions: Acute Kidney Injury
Interventions: Niyad (nafamostat mesylate), Placebo (0.9% NaCl); Device
Lead sponsor: Talphera, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • Orlando, Florida • Detroit, Michigan + 7 more

Conditions: Labor
Interventions: Ephedrine, Normal Saline Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Trigger Finger Disorder
Interventions: Dexamethasone Sodium Phosphate, Xylocaine, Sodium Chloride; Drug
Lead sponsor: Kenneth Taylor, M.D.; Other
Eligibility: 18 Years to 90 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Thoracic Diseases, Postoperative Pain, Opioid Use
Interventions: Liposomal bupivacaine, Bupivacaine Injection; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo

Steroids in Occipital Nerve Block for Treatment of Headache

The Role of Endothelin in the Supine Hypertension of Autonomic Failure

The Effect of RNS60 on ALS Biomarkers

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)

GSK2251052 in the Treatment of Complicated Intra-abdominal Infections

Effect of Postop Steroids on Cardiovascular/Respiratory Function in Neonates Undergoing Cardiopulmonary Bypass

Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction

Aging and Reward System Response to Inflammation and Anxiety Study

A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients

Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers

CAMPR-II RWE TRIAL: A Saline-hydrated Allogeneic Dual-layer Amniotic Membrane Product or a Synthetic, Resorbable Polymeric Wound Matrix to a Coarsened Exact Matched Retrospective Control Cohort of Hard to Heal DFUs and VLUs

Isotonic Solutions and Major Adverse Renal Events Trial in the Non-Medical Intensive Care Unit (SMART-SURG)

Adult Patients Undergoing Open Colectomy MA402S23B303

Nafamostat Efficacy in Phase 3 Registrational CRRT Study

Impact of Prophylactic Ephedrine on Fetal Heart Tracing and Uterine Tetanic Contraction After CSE

Pain With Trigger Finger Injection: A Comparison of Steroid Alone Versus Steroid/Lidocaine Mixture

Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial